Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine Cagrilintide vs Eloralintide: Which Amylin Receptor Agonist Shows Stronger Research Results? Xcel Peptides Development of the novel amylin receptor activators with nanomolar potency by peptide mutagenesis bioRxiv Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library A Review of Incretin Therapies Approved and in Late Stage Development for Overweight and Obesity Management Endocrine Practice